secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inspire Medical Systems, Inc. (INSP)
CIK:        0001609550
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0001609550-23-000032
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inspire Medical Q1 revenue up 84% to $127.9M; raises FY 2023 guidance to $580-590M
--------------------------------------------------------------------------------

- Revenue $127.9M (+84% YoY); U.S. revenue $124.5M (+87% YoY); gross margin 84.4%.
- Net loss $15.4M ($0.53 diluted EPS) vs $16.7M ($0.61) prior-year; cash $452.1M.
- Added 68 new U.S. centers (total 973) and 17 new sales territories (total 242) in Q1.
- Raised FY 2023 revenue guidance to $580-590M from $560-570M; maintained gross margin 83-85%.
- FDA approved therapy for pediatric Down syndrome (age 13+); finalized Belgium reimbursement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609550/000160955023000032/0001609550-23-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609550/000160955023000032/insp-20230502.htm
  HTML page:      https://secwatch.observer/filing/0001609550-23-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer